Publication
International arbitration report
In this edition, we focused on the Shanghai International Economic and Trade Arbitration Commission’s (SHIAC) new arbitration rules, which take effect January 1, 2024.
Author:
United States | Publication | February 18, 2022
On February 17, 2022, federal OSHA announced its initiative urging healthcare and related industries to take immediate actions to help make 2022 safer for their employees. OSHA noted an almost 250 percent increase in injury and illness incidence rates among healthcare and social assistance workers commencing in 2020, largely attributed to the COVID pandemic, and leading to combined totals greater than any other American industry.
To that end, OSHA continues to work on its final standard to protect healthcare workers from COVID. In the interim, OSHA emphasizes that employers must continue to comply with their obligations under the General Duty Clause, and the Personal Protective Equipment, Respiratory Protection and other relevant standards to protect employees from COVID hazards in the workplace.
Moreover, OSHA states that employers should create and implement proactive safety and health programs that address recognized hazards, training and preventive measures to keep workers safe. Companies are encouraged to utilize local OSHA On-Site Consultation personnel (1-800-321-OSHA (6742) and OSHA's program website) to discuss program development and conduct on-site safety and health evaluations.
Publication
In this edition, we focused on the Shanghai International Economic and Trade Arbitration Commission’s (SHIAC) new arbitration rules, which take effect January 1, 2024.
Publication
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Publication
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023